Hikma expands licensing agreement with Celltrion for Remsima® subcutaneous formulation in MENA

Hikma expands licensing agreement with Celltrion for Remsima® subcutaneous formulation in MENA

London, United Kingdom– (AETOSWire) Hikma Pharmaceuticals PLC (Hikma), the multinational pharmaceutical company, announces an exclusive licensing agreement with South Korea-based Celltrion, Inc. and Celltrion Healthcare, Inc. (Celltrion) for Remsima® subcutaneous (SC), the first subcutaneous formulation of infliximab. The agreement provides Hikma with exclusive rights to commercialise Remsima® SC, the world’s first subcutaneous formulation of infliximab, in all of its MENA markets.  It builds on Hikma’s existing partnership with Celltrion for three of its biosimilar products, Truxima® (rituximab),  Remsima® (infliximab) and Herzuma® (trastuzumab). Remsima® SC is used in the treatment of rheumatoid…